atezolizumab
Selected indexed studies
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (N Engl J Med, 2020) [PMID:32402160]
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. (Lancet Oncol, 2019) [PMID:31122901]
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. (Lancet, 2017) [PMID:27979383]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (2020) pubmed
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. (2019) pubmed
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. (2017) pubmed
- Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. (2025) pubmed
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). (2021) pubmed
- Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. (2021) pubmed
- Pembrolizumab and atezolizumab in triple-negative breast cancer. (2021) pubmed
- Atezolizumab for the treatment of breast cancer. (2020) pubmed
- Atezolizumab: A Review in Extensive-Stage SCLC. (2020) pubmed
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. (2019) pubmed